Drs. Lisa Porter and John Trant from the University of Windsor are working to develop a drug to block a protein that is elevated in some types of aggressive cancer. Disrupting the activity of this unique protein complex could slow or stop the disease. By providing researchers such as Porter and Trant with funding support and access to expertise, OICR’s Cancer Therapeutics Innovation Pipeline initiative is enabling the development of the next wave of made-in-Ontario cancer therapies.
Technology·Prostate cancer
Research co-led by OICR is helping advance understanding of the biology behind prostate cancer spreading. Why do some prostate cancers grow slowly for years, while others progress quickly to life-threatening metastatic disease? An international team…
Article·
